RU 01. Expression of hMOF histone acetyltransferase in renal clear cell carcinoma tissues and its clinical significance

Objective: The expression of hMOF protein in renal cell carcinoma tissues is measured to investigate its association with the clinical characteristics of renal cancer patients.

Methods: Immunohistochemistry and qRT-PCR were employed to detect the difference in hMOF expression levels between normal kidney and renal cell carcinoma tissues and determine the association between HMOF expression and the clinical characteristics of renal cell carcinoma patients.

Results: QRT-PCR findings showed that four of the nine patients (44.4%) had significantly declined mRNA levels. Immunohistochemical results showed that hMOF protein expression was negative or weakly positive in the renal cell carcinoma tissues of 39 patients (62.1%, 39/66), compared to that in the adjacent normal tissue of only 4 patients (6.1%, 4/66), and the difference was significant (P<0.05). Compared to Fuhrman I to II, hMOF expression in renal cell carcinoma Fuhrman Ⅲ was remarkably lower with significant differences (P<0.05). HMOF expression was significantly lower in poorly differentiated renal cell carcinoma compared with the welldifferentiated group, and the differences were also significant (P<0.05). In addition, patients with renal cell carcinoma and decreased hMOF protein levels were at risk of metastases to regional lymph nodes and distant organs.

Conclusions: The expression of hMOF protein is significantly lower in renal cell carcinoma, particularly those with worse pathological stage and Fuhrman grade, suggesting an association between the protein and the occurrence and development of renal cell carcinoma as well as the severity.